OncoMatch/Clinical Trials/NCT05702229
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Is NCT05702229 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for gastric cancer.
Treatment: Rilvegostomig · Volrustomig · FOLFOX · XELOX · AZD0901 · 5-Fluorouracil · Capecitabine — This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Gastric Cancer
Biomarker criteria
Required: CLDN18 central lab confirmed Claudin18.2 status
Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 is open for recruitment.
Required: HER2 (ERBB2) overexpression (3+ by IHC, or 2+ by IHC and positive by in situ hybridisation)
Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune-oncology agent
Previous treatment with an immune-oncology agent.
Cannot have received: Claudin18.2 targeted therapy
Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4 is open for recruitment).
Cannot have received: MMAE-containing therapy
Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4 is open for recruitment).
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
Liver function
Adequate organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Los Angeles, California
- Research Site · Los Angeles, California
- Research Site · Baton Rouge, Louisiana
- Research Site · Grand Rapids, Michigan
- Research Site · New Hyde Park, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05702229 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CLDN18?
Yes, CLDN18 central lab confirmed Claudin18.2 status is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages